磷酸盐:原发性甲状旁腺功能亢进的一种被低估的成分。

IF 6.1 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-10-31 DOI:10.1016/j.beem.2023.101837
Sanjay Kumar Bhadada , Jayaditya Ghosh , Rimesh Pal , Soham Mukherjee
{"title":"磷酸盐:原发性甲状旁腺功能亢进的一种被低估的成分。","authors":"Sanjay Kumar Bhadada ,&nbsp;Jayaditya Ghosh ,&nbsp;Rimesh Pal ,&nbsp;Soham Mukherjee","doi":"10.1016/j.beem.2023.101837","DOIUrl":null,"url":null,"abstract":"<div><p><span>Primary hyperparathyroidism<span> (PHPT) is a systemic disease that affects all the systems of the body, specifically the bones and the kidneys. Its main action is on </span></span>calcium homeostasis<span><span><span>. It tries to preserve the body’s calcium level at the cost of phosphate. The criteria for surgery in asymptomatic PHPT patients revolve around raised serum calcium levels, renal dysfunction or </span>nephrolithiasis<span>, and bone health. It does not take into account the serum phosphate levels. Depending on the serum level, </span></span>Hypophosphatemia<span><span> is divided into mild, moderate, and severe categories. In PHPT, several studies have suggested that asymptomatic PHPT patients with moderate hypophosphatemia may warrant surgical intervention. Treatment of hypophosphatemia in PHPT is based upon the degree of hypophosphatemia, and treatment is given according to that oral or </span>intravenous route; after surgical and medical treatment of PHPT, phosphate levels gradually normalized. But even after these considerations, phosphate levels in PHPT are not given much importance.</span></span></p></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"38 2","pages":"Article 101837"},"PeriodicalIF":6.1000,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Phosphate: An underrated component of primary hyperparathyroidism\",\"authors\":\"Sanjay Kumar Bhadada ,&nbsp;Jayaditya Ghosh ,&nbsp;Rimesh Pal ,&nbsp;Soham Mukherjee\",\"doi\":\"10.1016/j.beem.2023.101837\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span>Primary hyperparathyroidism<span> (PHPT) is a systemic disease that affects all the systems of the body, specifically the bones and the kidneys. Its main action is on </span></span>calcium homeostasis<span><span><span>. It tries to preserve the body’s calcium level at the cost of phosphate. The criteria for surgery in asymptomatic PHPT patients revolve around raised serum calcium levels, renal dysfunction or </span>nephrolithiasis<span>, and bone health. It does not take into account the serum phosphate levels. Depending on the serum level, </span></span>Hypophosphatemia<span><span> is divided into mild, moderate, and severe categories. In PHPT, several studies have suggested that asymptomatic PHPT patients with moderate hypophosphatemia may warrant surgical intervention. Treatment of hypophosphatemia in PHPT is based upon the degree of hypophosphatemia, and treatment is given according to that oral or </span>intravenous route; after surgical and medical treatment of PHPT, phosphate levels gradually normalized. But even after these considerations, phosphate levels in PHPT are not given much importance.</span></span></p></div>\",\"PeriodicalId\":8810,\"journal\":{\"name\":\"Best practice & research. Clinical endocrinology & metabolism\",\"volume\":\"38 2\",\"pages\":\"Article 101837\"},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2023-10-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Best practice & research. Clinical endocrinology & metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1521690X23001112\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Best practice & research. Clinical endocrinology & metabolism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521690X23001112","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

原发性甲状旁腺功能亢进症(PHPT)是一种影响身体所有系统的系统性疾病,尤其是骨骼和肾脏。它的主要作用是对钙稳态。它试图以磷酸盐为代价来保持身体的钙水平。无症状PHPT患者的手术标准围绕血清钙水平升高、肾功能障碍或肾结石以及骨骼健康。它没有考虑血清磷酸盐水平。根据血清水平,低磷酸盐血症分为轻度、中度和重度。在PHPT中,几项研究表明,患有中度低磷血症的无症状PHPT患者可能需要手术干预。PHPT中低磷血症的治疗基于低磷血症程度,并根据口服或静脉注射途径进行治疗;经过PHPT的手术和药物治疗后,磷酸盐水平逐渐正常化。但即使经过这些考虑,PHPT中的磷酸盐水平也没有得到太多重视。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Phosphate: An underrated component of primary hyperparathyroidism

Primary hyperparathyroidism (PHPT) is a systemic disease that affects all the systems of the body, specifically the bones and the kidneys. Its main action is on calcium homeostasis. It tries to preserve the body’s calcium level at the cost of phosphate. The criteria for surgery in asymptomatic PHPT patients revolve around raised serum calcium levels, renal dysfunction or nephrolithiasis, and bone health. It does not take into account the serum phosphate levels. Depending on the serum level, Hypophosphatemia is divided into mild, moderate, and severe categories. In PHPT, several studies have suggested that asymptomatic PHPT patients with moderate hypophosphatemia may warrant surgical intervention. Treatment of hypophosphatemia in PHPT is based upon the degree of hypophosphatemia, and treatment is given according to that oral or intravenous route; after surgical and medical treatment of PHPT, phosphate levels gradually normalized. But even after these considerations, phosphate levels in PHPT are not given much importance.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
11.90
自引率
0.00%
发文量
77
审稿时长
6-12 weeks
期刊介绍: Best Practice & Research Clinical Endocrinology & Metabolism is a serial publication that integrates the latest original research findings into evidence-based review articles. These articles aim to address key clinical issues related to diagnosis, treatment, and patient management. Each issue adopts a problem-oriented approach, focusing on key questions and clearly outlining what is known while identifying areas for future research. Practical management strategies are described to facilitate application to individual patients. The series targets physicians in practice or training.
期刊最新文献
Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model Recent progress in molecular classification of phaeochromocytoma and paraganglioma Overview of recent guidelines and consensus statements on initial screening and management of phaeochromocytoma and paraganglioma in SDHx pathogenic variant carriers and patients Editorial Board Metabolic and cardiovascular risks of hormone treatment for transgender individuals
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1